UNSPSC 51112402: Dacarbazine

This classification denotes a triazene compound with the molecular formula C6H10N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GR28W0FJI, chemically known as 5-(3,3-dimethyltriaz-1-en-1-yl)-1h-imidazole-4-carboxamide but more generally known as dacarbazine, which bears US NIH Compound Identifier 5281007. European Medicines Agency schedules Dacarbazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06882MIG.

UNSPSC 51112402 Dacarbazine is a Commodity code covering procurement of this chemotherapy agent by state and local health systems, corrections departments, and other public healthcare facilities. Dacarbazine is a cytotoxic alkylating agent used primarily in treatment of melanoma and Hodgkin lymphoma; state and local buyers source it through pharmaceutical wholesalers, group purchasing organizations, and direct manufacturers. The code reflects routine pharmaceutical inventory procurement rather than specialized compounding or clinical trial supply. Issuing bodies include state health departments, county hospital systems, correctional healthcare programs, and public university medical centers that operate inpatient oncology units or day treatment facilities.

The source provided contains no recent state and local contract opportunities tagged to this code, making it impossible to characterize geographic activity, issuing-body frequency, or representative recent solicitations. Without posted RFPs, RFQs, ITBs, or IFBs in the record, market activity cannot be assessed from procurement notice data.